Analytical Testing Market Intelligence


With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)


 No Additional Benefits

Subscription Benefits:

  • PRO access to New Beroe LiVE*
  • Unlimited updates on the Report*
  • Supplier Watchlist for 3 suppliers*
  • Supplier Shortlisting Tool*

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)


*These features will be unlocked on the new Beroe LiVE when it launches (Q3, 2020)

Are you looking for answers on Analytical Testing category?

Are you looking for answers on Analytical Testing category?

  • What are the key trends in Analytical Testing category?
  • Am I paying the right price?
  • Am I working with the right supplier?
  • What are the major challenges and risks in Analytical Testing industry?
  • How is Analytical Testing industry performing?

Over 50,000+ users trust Beroe

Report Coverage

  • PDS Outsourcing Spend
  • Global Trade Dynamics
  • Supplier Landscape

Market Size

Global Market Size

$9.1 Bn


5.5 Percent

Table of contents

  1. Analytical Testing industry Executive Summary
  2. BREXIT Impact
  3. Early Phase Clinical Snapshot
  1. Analytical Testing industry Market Analysis
  2. Global Market Size and Growth Forecast - Pharmaceutical development services
  3. Global Outsourcing Market Trend
  4. Outsourcing Adoption Trends - Analytical Testing Services
  5. Growth Drivers and Constraints
  6. Market Trends
  7. Porter’s Five Forces Analysis
  8. Regional Analysis - PDS
  9. Regional Analysis - Analytical Testing Services
  1. Analytical Testing industry Supply Market Overview
  2. Supplier Analysis
  3. Supplier Profiling
  4. Developments & Expansions
  5. Merger & Acquisitions
  1. Analytical Testing industry Sourcing Practices
  2. Sourcing Practices
  3. Cost Analysis - Analytical Testing Services

Want a more detailed personalised report?

Global Market Size and Growth Forecast –Analytical Testing industry

  • PDS accounts for about 5 percent of the total pharma R&D market. This market is estimated to increase from $7 billion in 2014 to $9.1 billion in 2018, seeing strong growth at a CAGR of around 5.5 percent, due to increased outsourcing by large pharmaceutical and biotechnology companies. This market is including both the large and small molecule development spend
  • The Phase I/II PDS development market accounts 30 percent of the entire PDS global spending at $2.1 billion in 2014


Global Outsourcing Market Trend

  • PDS outsourcing spend is expected to increase from $3.15 billion to $4.1 billion in 2018
  • Outsourcing budgets have increased in recent years, swinging from contractions to expansion after the 2008 recession
  • Pharma is maintaining its stance on outsourcing as a cost savings strategy
  • Demands for biologics is a boon for contract manufacturing and contract research organizations

Growth Drivers and Constraints


Increased investment in R&D

  • Increased investments at the discovery and early development phases are leading to robust pipelines and creating demand for greater clinical--scale manufacturing capacity.

Increase in biologic drugs

  • The percentage of expenditure going towards biologics development and outsourcing expenditure have both risen over last year.

Broad array of services offering

  • CDMOs are increasingly motivated to offer an expanded array of enhanced drug-delivery technologies, giving their customers broader options for patient care. Delivery technologies can include various targeted and timed release/dissolution and formulation technologies.

Increase in drug molecule complexity

  • Drug molecules are becoming more complex and increasingly require both advanced synthesis and formulation expertise to realize cost-effective, efficacious medicines


Pressure of cost reductions

  • The pressure on pharmaceutical firms to reduce costs was transferred to suppliers, which translated into reduced profit margins for suppliers.

Decline in number of initial public offerings (IPO)

  • Without public markets, the industry could see a sharp drop in IND filings, and in the demand for CDMO services, as it did in 2010.

Increasing pharmaceutical In-house capability

  • The pharma-biotech are investing significantly in internal manufacturing capabilities, through the expansion of existing or additional new manufacturing facilities and/or the acquisition of production capability


With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)


Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.


COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)